Stuart Crow – Non Executive Chairman – Lake Resources N.L. (ASX:LKE, OTC: LLKKF) is a responsible lithium developer utilising state of-the-art ion exchange extraction technology for production of sustainable, high purity lithium from its flagship Kachi Project in Catamarca Province within the Lithium Triangle in Argentina. Lake also has three additional early-stage projects in this region.
Copyright 2024 – Finance News Network
16 May 2023 - ABx Group Limited (ASX:ABX) CEO and Managing Director Dr Mark Cooksey discusses the advantages of ionic clay rare earths deposits, the company's exploration program, its plays for a scoping study and a pilot plant, and its new process to develop fluorine from aluminium smelting waste.
29 07 2024 - Bryan Quinn - CEO & Managing Director - Aurelia Metals (ASX:AMI) is an Australian mining and exploration company with a highly strategic landholding, and two operating mines in New South Wales (NSW). The Peak Mine is in the Cobar Basin in western NSW, and the Dargues Mine is in south-eastern NSW. The Hera mining operation, also located in the Cobar Basin, has ceased and the surface facilities have been placed into care and maintenance.
16 Aug 2023 - Tom Spurling - Executive Director - Nova Eye Medical (ASX:EYE) is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
14 Dec 2022 - RareX Limited (ASX:REE) Managing Director Jeremy Robinson discusses progress at the Cummins Range rare earths project and a potential resource upgrade.
11 Jun 2024 - Glen Finegan, Lead Portfolio Manager of Skerryvore, discusses the company's bottom-up approach to investing in emerging markets, emphasising governance, pricing power, and diversification as key drivers of success.
15 Feb 2023 - The bench-scale test work indicates the alternative process has the potential to improve processing reliability and feed-salt quality, positively impact costs and accelerate production ramp-up.
25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
20 Sep 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the FDA's award of orphan status and rare paediatric disease designation for the company's DUNP19 technology.
